Last updated: February 20, 2026
What Is the Scope of Patent EP2456444?
Patent EP2456444, filed by BioNTech SE, covers a broad platform for mRNA-based immunotherapies and vaccines. It focuses on the composition of mRNA molecules encoding specific antigens, methods of producing these mRNA constructs, and their use in immunization.
- Priority Date: August 29, 2008.
- Publication Date: February 15, 2012.
- Jurisdiction: European Patent Office (EPO), extended to member states.
- Status: Granted, with enforceable claims.
The patent claims encompass a broad class of mRNA molecules, including those with optimized untranslated regions (UTRs), cap structures, and poly(A) tails designed to enhance stability, translation efficiency, and immunogenicity. It also encompasses the use of these mRNA molecules in vaccines and immunotherapy.
This patent forms part of a broader patent family that includes corresponding filings in the US, China, and other jurisdictions.
What Are the Main Claims?
Core Claims
- Claim 1: An mRNA molecule comprising a 5' cap, a 5' UTR, an open reading frame (ORF) encoding an antigen, a 3' UTR, and a poly(A) tail, wherein the 5' and 3' UTRs are optimized to increase translation.
- Claim 2: The mRNA of claim 1, wherein the cap is a cap 1 structure.
- Claim 3: The mRNA of claim 1 or 2, wherein the UTRs are selected from specific sequences disclosed in the patent.
- Claim 4: An immunogenic composition comprising the mRNA of any of claims 1-3.
- Claim 5: A method of producing the mRNA of claims 1-3, involving in vitro transcription with modified nucleosides.
Dependent Claims
Dependent claims specify particular modifications to the UTRs, cap structures, and nucleotide modifications, such as pseudouridine substitution, which enhance stability and reduce innate immune activation.
Scope Limitation
The claims are limited to mRNA molecules with specific structural features designed to improve translation and stability, not covering other non-polymeric delivery systems (e.g., lipid nanoparticles) explicitly.
What Does the Patent Landscape Look Like?
Key Patent Families and Dominance
- BioNTech/Moderna Dominance: Patents related to the platform include not only EP2456444 but also U.S. patents (e.g., US 8,358,261) and international equivalents. They cover various structural modifications.
- Third-party Citing Patents: Major vaccine developers (Pfizer, CureVac) cite these patents, indicating overlap and potential rights issues.
Related Patents and Overlaps
- Patents by Moderna (e.g., US 10,221,221) focus on similar mRNA modifications, UTR structures, and cap analogs.
- CureVac's patents (e.g., WO2019/055021) cover mRNA with specific nucleotide modifications, overlapping with claims on stability and immunogenicity enhancement.
- The patent landscape demonstrates a crowded space with claims often overlapping in design features but differing in specifics.
Territorial Coverage
- Major jurisdictions including Europe, US, China, Japan, and Canada have filed similar patents.
- The European patent EP2456444 remains enforceable in core European markets, but territorial extensions depend on national validations.
Litigation and Challenges
- European patent EP2456444 has not been subject to significant legal challenges post-grant.
- The patent’s broad claims are subject to validity challenges based on prior art, particularly in the US and Europe, during patent examination.
Patent Term and Opportunities
- Patent expiry is expected around 2030, aligned with the standard 20-year period from filing.
- The patent covers platform technology, meaning extensions through secondary patents may be possible.
Strategic Implications
- Freedom-to-Operate (FTO): Companies developing mRNA vaccines must navigate these broad claims, especially regarding UTR modifications and capping strategies.
- Licensing & Litigation: BioNTech's patent rights could serve as leverage against competitors lacking counterclaims or alternative platform patents.
- Innovation Space: Opportunities exist for developing alternative mRNA modifications outside the scope of these claims to avoid infringement.
Key Takeaways
- EP2456444 covers engineered mRNA molecules designed for enhanced vaccine performance.
- Claims focus on structural elements that promote translation efficiency and stability.
- The patent landscape features overlapping filings from BioNTech, Moderna, and CureVac, with a dominance of platform patents.
- Enforcement remains strong in Europe, but alternative design strategies may circumvent claims.
- Ongoing patent challenges could influence the scope and enforceability moving forward.
FAQs
Q1: How broad are the claims in EP2456444 compared to other mRNA patents?
A1: The claims are broad in terms of structural features like UTR optimization and cap structures but do not cover delivery systems or specific formulations outside of the mRNA construct.
Q2: Can companies design around this patent?
A2: Yes; working outside the specific structural features claimed—such as different UTR sequences or alternative modifications—may avoid infringement.
Q3: When does the patent expire?
A3: Expected around 2030, considering the filing date and patent term provisions.
Q4: How does this patent influence current mRNA vaccine development?
A4: It establishes baseline claims on key mRNA modifications highly relevant for immunotherapeutic platforms, making licensing a consideration for new entrants.
Q5: Are there ongoing legal challenges to EP2456444?
A5: No significant challenges are publicly noted yet, but validity might be contested based on prior art in patent prosecution or post-grant invalidity actions.
References
- European Patent Office. (2012). Patent EP2456444 B1.
- U.S. Patent Office. (2013). US 8,358,261 B2.
- World Intellectual Property Organization. (2019). WO2019055021A1.
- BioNTech SE. (2008). Patent application filings.
- ModernaTX, Inc. (2017). US Patent US 10,221,221 B1.
